Cancer Drugs 2 Flashcards Preview

Hematology And Oncology > Cancer Drugs 2 > Flashcards

Flashcards in Cancer Drugs 2 Deck (40):
1

Bevacizumab mechanism of action

Monoclonal antibody against VEGF (inhibits angiogenesis)

2

Bevacizumab clinical use

Solid tumors: 1. Colorectal 2. Renal

3

Bevacizumab toxicity

1. Hemorrhage
2. Blood clots
3. Impaired wound healing

4

Vemurafenib mechanism of action

Small molecule inhibitor of BRAF oncogene + melanoma

5

Imatinib toxicity

Fluid retention

6

Imatinib clinical use

1. CML (BCR-ABL)
2. GI stromal tumors (c kit)

7

Imatinib mechanism of action

Tyrosine kinase inhibitor of BCR-ABL (Philadelphia ch) and c-kit (gi stromal tumors)

8

Rituximab mechanism of action

Monoclonal antibody against CD20 (B-cells)

9

Rituximab toxicity

Increased risk of progressive multifocal leukoencephalopathy

10

Rituximab clinical use

1. Non-Hodgkin
2. CLL
3. RA
4. ITP

11

Cisplatin, carboplatin mechanism of action


Cross link dna

12

Cisplatin carboplatin clinical use

1. Testicular ca
2. bladder ca
3. Ovary ca
4. Lung ca

13

Cisplatin carboplatin toxicity

1. Nephrotoxicity
2. Ototoxicity
3. peripheral neuropathy

14

How to prevent cisplatin or carboplatin associated nephrotoxicity

Amifostine (free radical scavenger) chloride (saline) diuresis

15

Etoposide, tenoposide - mechanism of action

Inhibits topoisomerase 2--> dna degradation

16

Etoposide tenoposide clinical use

1. Solid tumors (testicular, small cell lung)
2. Lymphoma
3. Leukemia

17

Etoposide tenoposide toxicity

1. Myelosuppression
2. Gi upset
3. Alopecia

18

Irinotecan, topotecan mechanism of action

Inhibit topoisomerase 1 and prevent DNA unwinding and replication

19

Irinotecan clinical use

Colon cancer

20

Topotecan clinical use

1. Small cell lung cancer
2. Ovarian

21

Irinotecan, topotecan toxicity

1. Severe myelosuppression
2. Diarrhea

22

Trastuzumab is also called

Herceptin

23

Trastuzumab (herceptin) toxicity

Cardiotoxicity

24

Trastuzumab (herceptin) clinical use

Her2 + breast cancer and gastric cancer

25

Trastuzumab (herceptin) mechanism of action

Monoclonal antibody against HER-2 (c-erbB2), a tyrosine kinase receptor. It kills cancer cells that overepress HER-2 by
A. inhibition of HER-2-initiated cellular signaling
B. Antibody depended cytotoxicity

26

2 SERMs

1. Tamoxifen
2. Raloxifene

27

SERMs (tamoxifen, raloxifene) clinical

Tamoxifen: breast cancer treatment
Raloxifene: prevent osteoporosis
Both: breast cancer prevention

28

Tamoxifen, raloxifene toxicity

Tamoxifen: 1. partial agonist in endometrium which increases the risk of endometrial cancer
Raloxifene: no increase in endometrial ca (antagonist in endometrial estrogen receptor)
both increases the risk of thromboembolic events and hot flashes

29

Prednisone, prednisolone mechanism of action

Various....1. Bind intracytoplasmic receptor 2. Alter gene transcription

30

Prednisone, prednisolone clinical use

A. Most commonly used glucocorticoids in cancer chemotherapy 1. CLL 2. Non-Hodgkin (part of combination)
B. Immunosuppressants (eg. Autoimmune disease)

31

Prednisone, prednisolone toxicity

Cushing-like, weight gain, central obesity, muscle break down, cataracts, acne, osteoporosis, hypertension, peptic ulcer, hyperglycemia, psychosis

32

cancer drugs that acts on S and G2

etoposide, tenoposide, irinotecan, topotecan

33

cancer drugs that acts only on S phase

antimetabolites

34

cancer drugs that act on G2

bleomycin

35

cancer drugs that acts on M phase

microtubule inhibitors

36

Cell cycle independent drugs

Platinum agents
Alkylating agents

37

hematologic drugs that are teratogenic

1. alkylating angents
2. warfarin

38

Cetuximab - mechanism of action

Monoclonal antibody against EGFR

39

Cetuximab - clinical use

1. stage IV CRC (wild-typeKRAS)
2. head and neck cancer

40

Cetuximab - adverse effects

1. rash
2. elevated LFTs
3. Diarrhea